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Abstract: Background/Objectives: In developing countries, spirometry has not been considered a part of routine medical 
check-up. The purpose of the study was to establish the usefulness of spirometry as a primary screening tool in detecting 
air flow obstruction (AFO) during routine medical check-up (RMC). 
Methods: This was a hospital based, retrospective, non-randomized case series study of 3696 participants, who presented 
to hospital for routine medical check-up. All subjects were assisted at the Pulmonary Medicine Department, from January 
2003 till December 2008 who, having met other inclusion criteria, underwent spirometry. Data were analyzed using 
proportion, group means, standard deviations and Pearson Chi Square test. 
Results: The overall yield from spirometry in detecting AFO was 211 patients (5.7%); 174 males (6.1%) and 37 females 
(4.4%) (P=0.158, Pearson Chi Square test). Greater age at presentation and BMI correlated significantly with AFO in the 
target group (P=<0.001; P=<0.005) respectively. Dyspnoea was the most frequent symptomatology observed in those 
diagnosed with AFO. 
Conclusion: These results suggest that spirometry during RMC for all persons can detect a significant number of patients 
with AFO particularly among the middle and older age groups with a low BMI. 
Keywords: Spirometry, airflow obstruction, routine medical check-up, early screening, epidemiology. 
INTRODUCTION 
  Air flow obstruction (AFO) is a universal health problem 
with a high morbidity and mortality rate such that the disease 
today presents a real public health problem and a major 
burden on health care facilities all around the world [1]. 
AFO particularly COPD at the moment is on the rise [2] in 
both developed and underdeveloped countries, moreover it 
has been projected to be the third leading cause of death 
globally by 2020 [3]. AFO today represents 90% of the 
patients with Chronic Obstructive Lung Disease (COPD). It 
is estimated that about 10% of the general population have 
the asymptomatic disease and 26% of the people above 45 
years of age have indications of AFO [4, 5]. However only a 
quarter of these are known to their physicians owing to the 
problem of early identification of the disease as well as late 
patient presentation in advanced stages [5, 6]. In a study 
carried out by Fukuchi et al. in Japan [7], it was noted that 
90.6% of the population with airflow obstruction were under 
diagnosed. Similarly in a community based research carried 
out by Pena et al. [8], 52% of the British general population 
had not been diagnosed as having COPD. 
  Spirometry is an important diagnostic modality for 
monitoring and management of various respiratory diseases 
and represents the main diagnostic tool for COPD by 
measuring the AFO [9, 10]. Nevertheless this diagnostic test  
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continues to be used very little in primary care setting 
especially in developing countries [11]. 
  Undiagnosed airflow obstruction due to non-usage of 
spirometry is common in the general population and is 
associated with impaired health status of the community 
especially in third world countries like Pakistan, where 
resources are limited and budgetary allocation to health 
inadequate. In this scenario our study carries huge 
implications for revolutionizing primary health care as 
spirometry has till date not been completely considered a 
part of routine medical examination despite the high burden 
of respiratory obstructive diseases. This could potentially be 
due to the fact that very few studies to evaluate the role of 
spirometry have been carried out in the context of the local 
population in underdeveloped countries where the 
prevalence of COPD is not known. The primary objective of 
our study was to establish the efficacy of spirometry in 
determining the prevalence of AFO in subjects of Asian 
origin to recommend it for all people on RMC. 
METHODS 
  This hospital based, retrospective, non-randomized and 
non-interventional case series study was carried out at 
Pulmonary Medicine department, Aga Khan University 
Hospital, Karachi, Pakistan beginning from January 2003 till 
December 2008. A total of 3696 participants presenting to 
hospital for routine medical check up were enrolled in the 
study according to the set out inclusion criteria. The study 
was carried out in accordance with the declaration of 
Helsinki of 1975 as revised in 1983. The primary outcome 
measure was the evaluation of spirometry in detecting air 
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  Only those patients fulfilling the following set out criteria 
were enrolled in the study: 
1.  Those who gave consent for participating in the study. 
2.  Participants of all ages and gender as determined by 
filled Performa with a definite history of 
symptomatology and demographic information. 
3.  Supervised Spirometry by a qualified technician. 
  Patients with the following pathologic state or problems 
were excluded from the study: 
1.  Previously diagnosed cases of Asthma, COPD or any 
other respiratory disease. 
2.  Abnormalities on chest X-ray like hyperinflation, 
hyperlucency of the lungs, and rapid tapering of the 
vascular markings. 
3.  Did not undergo Spirometry. 
  AFO was defined according to GOLD guidelines 2006, 
in which FEV1% is 70% or less. According to our followed 
criteria FEV1% is the ratio of Forced Expiratory Volume 
(FEV1) to Forced Vital Capacity (FVC)
 [10]. The study was 
carried out in two parts, first the participants were made to 
fill out a well structured questionnaire regarding their 
baseline demographics like weight, height and 
symptomatology, followed by pulmonary function tests 
administered using a flow type spirometer by a well trained 
and experienced laboratory technologist according to 
published data and GOLD guidelines for vital capacity (VC), 
forced vital capacity (FVC) and forced expiratory volume in 
one second (FEV1) to reduce any recruitment bias i.e. 
regression to mean. These parameters were obtained from 
the best of each curve recorded for the maximal inspiration, 
maximal slow expiration, maximal inspiration and maximal 
forced expiration procedures meeting American Thoracic 
Society (ATS) acceptability and repeatability criteria [12]. 
The investigators performed regular calibration checks. 
  Classification of subjects was done according to age, sex, 
BMI and symptomatology criteria. If the subject underwent 
several medical checkups during our study period, the latest 
data was used for analysis. The prevalence of AFO was the 
ratio of persons with FEV1% less than 70% (FEV1/FVC70) 
respectively. Subjects were divided into three age groups (1) 
35 years in age (2) between 36-55 years and (3) >55years. 
Subjects were divided into four groups with respect to BMI 
according to WHO criteria [13]: (1) <18.5 Kg/m
2 (Under 
Wt) (2) 18.5-22.9 Kg/m
2 (Normal) (3) 23-24.9 Kg/m
2 (Over 
Wt) (4) >25 Kg/m
2 (Obese). BMI was calculated as body 
weight expressed in kilograms divided by the square of body 
height in meters. 
  Data for physical and respiratory variables were 
expressed as means ± standard deviation (S.D). The 
prevalence of AFO was characterized by age, sex, BMI and 
symptomatology of the subjects. In our study all the data was 
collected on medical check ups. Data were entered in 
Statistical Package for Social Sciences (SPSS version 16) 
and analysis of the data was done using frequencies, 
proportions, group means, standard deviations and Pearson 
Chi Square test. Alpha level of 0.05, power of 0.8 and 
Confidence interval of 95% were selected for analysis. 
RESULTS 
  A total of 3696 subjects based on the inclusion criteria 
were incorporated in the study. 2861 males (77%) and 835 
females (23%) aged between 5 and 90 years (mean ± std. 
dev= 47 ± 13 years) were included in the study. The male to 
female ratio was 3.4:1 with a mean height of 163 +/- 78 cm, 
weight of 77.6 +/- 101.5 kg and FEV1% of 85 +/-136. The 
baseline characteristics of subjects of each age and sex group 
are presented in Table 1. 
  Out of the total cohort of subjects, 787 participants 
(21.3%) were 35 yrs in age, 1989 were between 36-55 
years (53.8%) and 920 were >55years of age (24.9%). The 
overall yield from spirometry in detecting AFO was 211 
patients (5.7%). One hundred and seventy four males (6.1%) 
out of 2861 total males and 37 females (4.4%) out of 835 
total females suffered from AFO according to GOLD 
guidelines. One hundred and thirty seven patients had mild 
degree of AFO while 46 and 28 patients suffered from 
moderate and severe AFO respectively. None of the subjects 
had very severe AFO; however 549 subjects were in the 
restrictive spirometry group. In most age groups, there was a 
Table 1.  Baseline Characteristics of Participants 
 
Age Groups (Mean±std.dev) 
Variables  Sex 
<35 Years  36-55 Years  >55 Years 
Total 
N (%)* 
M 
F 
657 (84) 
123 (16) 
1536 (77) 
460 (23) 
668 (73) 
252 (27) 
2861 (77) 
835 (23) 
Weight (kg) 
M 
F 
94 ± 400 
63 ± 18 
81 ± 15 
70 ± 14 
77 ± 14 
70 ± 17 
83 ± 192 
69 ± 16 
Height (cm) 
M 
F 
174 ± 325 
156 ± 16 
170 ± 10 
156 ± 9 
168 ± 8 
154 ± 10 
171 ± 114 
155 ± 11 
BMI (kg/m
2) 
M 
F 
34 ± 144 
38 ± 129 
30 ± 69 
29 ± 14 
27 ± 7 
31 ± 23 
30 ± 86 
31 ± 52 
FEV1% (%) 
M 
F 
85 ± 7 
88 ± 6 
83 ± 7 
102 ± 386 
79 ± 10 
82 ± 8 
83 ± 8 
94 ± 287 
N: Number of subjects; BMI: Body Mass Index; FEV1%: Percentage of Forced Expiratory Volume (FEV) in one second for Forced Vital Capacity (FVC). 
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trend of higher prevalence of AFO in males as compared to 
females, however statistical significance could not be 
reached (P= 0.158, Pearson Chi square Test). The 
distribution of AFO by age was significantly related with 19 
subjects in those 35 years of age (2.4%), 79 subjects in 
those between 36-55 years (3.9%) and 113 in those >55 
years (12.3%) (Table 2). 
Table 2.  Prevalence of COPD in Participants in Relation to 
Age, Sex & BMI 
 
FEV1% N (%)* 
Variables 
 70 %  > 70 % 
P-Valueº 
Age Groups 
35 
36-55 
>55 
 
19 (2) 
79 (4) 
113 (12) 
 
768 (98) 
1910 (96) 
807 (88) 
 
 
<0.001 
Sex 
Male 
Female 
 
174 (6) 
37 (4) 
 
2687 (94) 
798 (96) 
 
0.158 
 
BMI 
<18.5(Under Wt) 
18.5-22.9(Normal) 
23-24.9(Over Wt) 
>25(Obese) 
 
11 (9.8) 
49 (8.7) 
34 (5.9) 
117 (4.8) 
 
101 (90.2) 
516 (91.3) 
544 (94.1) 
2324 (95.2) 
 
 
0.006 
*FEV1% is the ratio of Forced Expiratory Volume (FEV1) to Forced Vital Capacity 
(FVC), The figures have been rounded to the nearest zero. 
ºPearson Chi square test. 
 
  There was no significant difference in the mean values of 
BMI across various age groups (Table 1). Out of the total 
subjects, 3019 participants (81.7%) had a BMI above normal 
i.e. above 23 Kg/m
2. However the highest prevalence of 
AFO was seen in the underweight group followed by normal, 
overweight and obese group respectively. The prevalence of 
COPD was significantly related to decreasing BMI 
(P=0.006). Table 2 presents a comparison of BMI and AFO. 
  Out of the 211 patients having FEV1% less than 70%, 95 
subjects suffered from dyspnoea (45%), 66 from chronic 
cough (31.3%), 61 from expectorant cough with sputum 
discharge (28.9%), 33 from wheeze (15.6%). All the 
symptoms were significantly related with AFO (P=<0.001), 
however there were no patients with complains of chest pain 
(P=1.00). Presenting symptomatology in subjects and its 
relation to COPD is shown in Table 3. 
DISCUSSION 
  The present study sought to investigate the efficacy of 
spirometry in determining the prevalence of AFO as gauged 
by FEV1/FVC (FEV1%)  70% in the Pakistani population of 
Asian origin, where a low screening rate for COPD persists 
despite the consensus in the medical community about the 
potential harmful effects of AFO particularly COPD on 
health if not prevented and treated in the early stages of the 
disease. The present study was motivated by the invariably 
late presentation and occurrence of AFO not only in Pakistan 
but world over [14]. 
  The prevalence of AFO in the study was 5.7%. In a cross 
sectional study carried out in the Spanish population, Jaén 
Díaz  et al. [15] estimated a prevalence in 16.4% of the 
population. In another community based project Takemura  
et al. [16] observed a prevalence of 3.6% in all subjects of 
Japanese origin without Bronchodilator Reversibility 
Testing. However comparison between our study and others 
is likely to be biased attributed to the different study 
population, setting and criteria used for assessing AFO and 
COPD. Age was significantly related to COPD in the study, 
with rising cases of AFO with increased age groups. Similar 
conclusions have been drawn from numerous studies carried 
through out the globe [15, 16]. Gender was not related to 
AFO in the target group, presumably due to the fact that 
women in Pakistan are most of the time housewives whereas 
men are commonly exposed to occupational and 
environmental respiratory hazards leading to AFO. 
Table  3.  Symptomatology Observed in Participants on 
Presentation 
 
FEV1% N (%)* 
Symptom 
 70 %  > 70 % 
P-Valueº 
Dyspnoea  
95 
(45) 
817 
(23.5) 
<0.001 
Cough 
66 
(31.3) 
550 
(15.8) 
<0.001 
Sputum 
61 
(28.9) 
497 
(14.3) 
<0.001 
Wheeze 
33 
(15.6) 
226 
(6.5) 
<0.001 
Chest pain 
0 
(0.0) 
2 
(0.1) 
1.00 
*FEV1% is the ratio of Forced Expiratory Volume (FEV1) to Forced Vital Capacity 
(FVC),  For the sake of simplicity the data of only those subjects with positive 
symptomatology is shown. 
ºPearson Chi Square test. 
 
  Smoking is a recognized risk factor for AFO and 
smoking rates provide a valuable method of estimating AFO 
prevalence in the general population. We assumed the 
smoking prevalence to be that of the general population 
(22%) [17, 18] and the rate of AFO in smokers to be around 
15-20% in line with international studies [19, 20]. On the 
basis of these statistics the prevalence of AFO in smokers for 
our set of population comes out to be highly significant. 
  COPD has been linked with a chronic state of 
inflammation which may be due to the release of 
inflammatory mediators like C-reactive protein (CRP) [21].
 
Chronic state of inflammation is associated with weight loss, 
muscle wasting and tissue depletion [22, 23]. In our study 
eleven subjects out of 112 (9.8%) in the underweight 
category were suffering from AFO while 117 subjects out of 
2441 (4.8%) in the obese category were suffering from AFO. 
This increased prevalence of AFO in the underweight 
category has been documented by other studies around the 
globe as well [21, 24, 25]. In a recent research carried out by 
Melbye  et al., [26]
  a strong link was recognized between 
bronchial airflow limitation and the circulating CRP level in 
an elderly population. On the other hand in a study 
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levels almost double with the rise in weight class. A 
relationship between COPD and BMI is increasingly being 
recognized, although the nature of this association to date 
remains unknown [28]
  hence these results should be 
interpreted with potential caution until a definite relationship 
has been proved. 
  Dyspnoea was found in the majority of the subjects 
diagnosed with AFO (45%). In a study conducted by Kömüs 
et al. [29], cough was found to be the predominant symptom 
in 77.6% of the population included in the at risk group 
while dyspnoea was the second most prevalent symptom in 
62.1% of the population. Similarly in another study 
conducted by Kornmann et al. [30], 84% of the patients 
diagnosed with COPD had cough followed by 70% of the 
patients suffering from exertional dyspnoea. The positive 
predictive value of other symptoms like cough, sputum 
discharge or wheeze were comparatively less than dyspnoea 
in our study, however previous studies carried out note the 
importance of simultaneous presence of two or more 
symptoms, as these symptoms almost double the chances of 
a positive diagnosis of AFO [31]. 
  All the participants included in our study were those who 
came for general medical checkup and had no prior history 
of AFO, then only were they referred for spirometry by the 
primary care physician; this helped us to remove any 
selection bias due to selection of subjects already suffering 
from AFO. The sample size involved was potentially large 
enough, however due to non-representative nature of the 
sample as well as being a hospital based study we cannot 
generalize the results of our study for the whole country 
based upon the existing statistics. Further more 
bronchodilation was not carried out to check reversibility. 
Despite these limitations the study gives an idea of the 
burden of unrecognized and hidden prevalence of AFO in 
the country due to its late presentation and holds important 
implications for policy makers for the future and will help 
them determine what future strategies and planning need to 
be undertaken to tackle this problem at the grass root level. 
  In conclusion, this study fulfills the objectives set by the 
study protocol for this project of assessing the various risk 
factors and the efficacy of spirometry in determining the 
prevalence of AFO in the population and advocates the use 
of early screening tests like spirometry for prevention and 
management of life threatening complications in AFO 
population. This study holds important implications for 
public health and highlights the high prevalence of 
undiagnosed AFO in the target population particularly those 
in higher age group with a low BMI. 
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